{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:14:53Z","timestamp":1766819693238,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) \u2265 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-na\u00efve patients strongly positive for PD-L1 (TPS \u2265 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019. The primary endpoints were centrally reviewed intracranial overall response rates (ORRs), centrally reviewed intracranial progression-free survival (cPFS), extracranial PFS, and overall survival were secondary endpoints. Forty-three patients from five centers were included. Surgical or local radiation therapy was administered to 31 (72%) patients, mostly before initiating ICI therapy (25\/31). Among 38\/43 (88.4%) evaluable patients, the intracranial ORR was 73%. The median PFS was 8.3 months. The cerebral and extracerebral median PFS times were 9.2 and 5.3 months, respectively. The median OS was 25.5 months. According to multivariate analysis, BM surgery before ICI therapy was the only factor significantly associated with both improved PFS (HR = 0.44) and OS (HR = 0.45). This study revealed the feasibility and outcome of front-line pembrolizumab treatment in this population with BM.<\/jats:p>","DOI":"10.3390\/curroncol31030126","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T09:13:08Z","timestamp":1711012388000},"page":"1656-1666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-727X","authenticated-orcid":false,"given":"Simon","family":"Nannini","sequence":"first","affiliation":[{"name":"Department of Oncology, Institut de Canc\u00e9rologie Strasbourg Europe, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-7303","authenticated-orcid":false,"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[{"name":"Department of Pneumology, UNIROUEN, LITIS Lab QuantIF Team EA4108, CHU Rouen, Normandie University, Rouen and Inserm CIC-CRB 1404, 76000 Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Centre R\u00e9gionale de Lutte Contre le Cancer Fran\u00e7ois Baclesse, 14000 Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Ricordel","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Centre Hospitalier Universitaire, 35000 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Demontrond","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Centre R\u00e9gionale de Lutte Contre le Cancer Fran\u00e7ois Baclesse, 14000 Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Abdallahoui","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut de Canc\u00e9rologie Strasbourg Europe, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyid","family":"Baloglu","sequence":"additional","affiliation":[{"name":"Department of Radiological, Centre Hospitalier Universitaire de Strasbourg, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[{"name":"Multidisciplinary Oncology and Therapeutic Innovations, APHM, INSERM, CNRS, CRCM, H\u00f4pital Nord, Aix Marseille University, 13015 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Centre Hospitalier, 94000 Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7735-5366","authenticated-orcid":false,"given":"Roland","family":"Schott","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut de Canc\u00e9rologie Strasbourg Europe, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: Summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/neuonc\/noz246","article-title":"Exclusion of patients with brain metastases from cancer clinical trials","volume":"22","author":"Patel","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13046-019-1426-2","article-title":"Immunotherapy of brain metastases: Breaking a \u201cdogma\u201d","volume":"38","author":"Valente","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_9","first-page":"e4446","article-title":"Efficacy of pembrolizumab and nivolumab in crossing the blood brain barrier","volume":"11","author":"Abid","year":"2019","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Guckenberger","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.21037\/jtd-2019-rbmlc-06","article-title":"WBRT for brain metastases from non-small cell lung cancer: For whom and when?-Contemporary point of view","volume":"13","author":"Rucinska","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13014-019-1237-9","article-title":"Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: Multi-national radiation treatment recommendations are heterogeneous","volume":"14","author":"Nieder","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: Pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","article-title":"Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors","volume":"14","author":"Hendriks","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.1200\/JCO.2021.39.15_suppl.9091","article-title":"First-line pembrolizumab monotherapy for PD-L1-positive (TPS \u2265 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort\u2014ESCKEYP trial (GFPC 05-2018)","volume":"39","author":"Descourt","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41591-023-02392-7","article-title":"Pembrolizumab in brain metastases of diverse histologies: Phase 2 trial results","volume":"29","author":"Brastianos","year":"2023","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.22.02561","article-title":"Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17\/05)","volume":"41","author":"Nadal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-0798","article-title":"PD-1\/PD-L1 blockers in NSCLC brain metastases: Challenging paradigms and clinical practice","volume":"26","author":"Sanmamed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","article-title":"Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/S0959-8049(16)31622-7","article-title":"2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets","volume":"51","author":"Brastianos","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4049\/jimmunol.179.2.845","article-title":"Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells","volume":"179","author":"Masson","year":"2007","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","article-title":"Outcomes in Patients with Non-small-cell Lung Cancer with Brain Metastases Treated with Pembrolizumab-based Therapy","volume":"22","author":"Sun","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jtho.2021.04.014","article-title":"Immunotherapy as Single Treatment for Patients with NSCLC with Brain Metastases: A Systematic Review and Meta-Analysis\u2014The META-L-BRAIN Study","volume":"16","author":"Camandaroba","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: A meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/3\/126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:17:23Z","timestamp":1760105843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/3\/126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["curroncol31030126"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31030126","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}